[ad_1]
A Florida-based company is trying to fight the aging process by taking the blood of young people and transfusing it to patients aged 30 and over in a new dubious trick that is sweeping the United States.
Ambrosia, founded in 2016 by Jesse Karmazin, a graduate of Stanford Medical School, has already established transfusion centers in five US cities: Los Angeles, Tampa, Omaha, Houston and San Francisco. Their macabre treatments start at just $ 8,000 for one liter and $ 12,000 for two.
Blood donors are between 16 and 25 years old, while patients are over 30 years old. So far, approximately 150 patients aged 35 to 92 have experienced the same "Young plasma treatments" and the company says that a waiting list has already been formed.
"Some patients had young blood and some older blood. I was able to do statistics about it and the results were really impressive. " Karmazin said previously. "And I thought it was the kind of therapy I would like to be available to me."
The idea was inspired by an experimental treatment called "parabiosis", which was conducted in mice and showed a reduction of two proteins badociated with cancer risks, although the study was both inconclusive and limited.
The company conducted a clinical trial involving 200 participants from June 2016 to January 2018. The study did not post any results on the US government's clinical trials website.
"The trial was an experimental study" David Cavalier, former chief operating officer of Ambrosia, said in September. "We have seen some interesting things and we plan to publish this data. And we want to start opening clinics where treatment will be available. "
The company lists the nebulous and ill-defined benefits to patient health such as "Renewed concentration, better memory and sleep, improved appearance and muscle tone", but has not yet provided empirical evidence to support these claims. This also does not take into account the placebo effect – participants who simply went to the clinic and participated in the study could easily have produced a positive confirmation bias.
In addition, the Food and Drug Administration has clbadified blood transfusions as "non-labeled" treatments, which means that they are approved as planned, but can also be applied as unconventional treatments without that it is necessary to demonstrate the alleged health benefits listed.
"They could very likely inflict bodily harm," UC Berkeley researcher Irina Conboy has issued a warning to Business Insider. "It is well known in the medical community – and this is also why we do not make transfusions frequently – that in 50% of patients there are very bad side effects. You are infused with the blood of someone else and it does not fit. "
Do you like this story? Share it with a friend!
Source link
